OsgoodEE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep, 1960; 9: 1–10.
5.
AlexanianRHautAKhanAU. Treatment for multiple myeloma. Combination chemotherapy with different melphalan regimens. JAMA, 1969; 208: 1680–85.
6.
Medical Research Council's Working Party for Therapeutic Trials in Leukaemia. Myelomatosis: Comparison of melphalan and cyclophosphamide therapy. Br Med J1971; 1: 640–41.
7.
Medical Research Council's Working Party on Leukaemia in Adults. Report on the second myelomatosis trial after five years of follow up. Br J Cancer1980; 42: 813–22.
8.
Medical Research Council's Working Party on Leukaemia in Adults. Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer1980; 42823–30.
9.
Medical Research Council's Working Party on Leukaemia in Adults. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Br J Cancer1985; 52: 153–58.
10.
BelchAShelleyWBergsagelD. A randomised trial of maintenance versus no maintenance melphalan and prednisolone in responding multiple myeloma patients. Br J Cancer, 1988; 57: 94–99.
11.
RiccardiAUcciGLuoniR. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cytostatic policy. Br J Cancer, 1994; 70: 1203–1210.
12.
HjorthMHellquistLHolmbergEMagnussonBRodjerSWestinJ. Initial versus deferred melphalan-prednisolone therapy for asymptomatic multiple myeloma stage I - a randomised study. Eur J Haematol, 1993; 50: 95–102.
13.
Medical Research Council's Working Party for Leukaemia in Adults. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet1992; 339: 200–205.
14.
BoccadoroMMarmontFTribaltoM. Multiple myeloma: VMCP / VBAP alternating combination chemotherapy is not superior to melphalan and prednisolone even in high risk patients. J Clin Oncol, 1991; 9, 444–48.
15.
GregoryWMRichardsMAMalpasJS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of publishedtrials. J Clin Oncol, 1992; 10: 334–42.
16.
BergsagelDE. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?Eur J Cancer Clin Oncol1989; 25: 159–61.
17.
McElwainTJPowlesRL. High-dose intravenous melphalan for plasmacell leukaemia and myeloma. Lancet, 1983; vol II: 822–24.
18.
AttalMHarousseauJ-LStoppaA-M. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med, 1996; 335: 91–97.
19.
BarlogieBJagannathSVesoleDH. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 1997; 89: 789–93.
20.
BrennerMKRillDRMoenRC. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet, 1993; 341: 85–86.
21.
BensingerVVIDemirerTBucknerCD. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant, 1996; 18, 527–31.
22.
BensingerWIBucknerCDAnasettiC. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood, 1996; 88: 2787–2793.
23.
BjorksrandBLjungmanPSvenssonH. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European group for blood and marrow transplantation. Blood, 1996; 88: 4711–18.
24.
VerdonckLFLokhorstHMDekkerAWNieuwenhuisHKPetersenEJ. Graft-versus-myeloma effect in two cases. Lancet, 1996; 347: 800–801.
25.
RussellNHMiflinGStainerCMcQuakerJGBienzNHaynesAPBessellEM. Allogeneic bone marrow transplantation for multiple myeloma. Blood1997: 89: 2610–17.
26.
SoutarRLWilsonBJDawsonAA. Incidence and mortality trends for multiple myeloma over thirty years in North East Scotland. Health Bull, 1996; 54: 232–40.
27.
AvvisatiGMandelliF. The role of interferon-a in the management of myelomatosis. In: BarlogieB, ed. Multiple Myeloma. Hematol Oncol Clin N Amer. Philadelphia: WB Saunders, 1992; 6 (2): 395–405.
28.
CooperMRDearKMcLntyreR. A randomised clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a cancer and leukaemia group B study. J Clin Oncol, 1993; 11: 155–160.
29.
OsterborgABjorkholmMBjoremanM. Natural interferon-a in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and m: a randomised study from the myeloma group of central Sweden. Blood, 1993; 6: 1428–34.
30.
CasassusPhPegourie-BandelierBSadounA. Randomised trial of interferon-a with VMCP/VBAP regimen as the induction phase of untreated multiple myeloma: results of the KIF multicentre trial. Blood, 1995; 96 (suppl 1): Abstract 1750.
31.
AbrahamsonGMBirdJMNewlandAC. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol, 1996; 94, 659–64.
32.
LudwigHCohenAMPolliackA. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol, 1995: 6, 467–76.
33.
OkenMMLeongTKayNEGreippPRVan NessBKyleRA. The effect of adding interferon (rINFa2) or high-dose cyclophosphamide to VBMCP to treat multiple myeloma: results from an ECOG phase m trial. Blood, 1995; 96 (suppl 1): Abstract 1749.
34.
Nordic Myeloma Study Group. Interferon-a2b added to melphalanprednisolone for initial and maintenance therapy in multiple myeloma. Ann Intern Med1996; 124: 212–22.
35.
JoshuaDEPennyRMatthewsJP. Australian leukaemia study group myeloma II: a randomised trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haematol, 1997; 97: 38–45.
36.
MandelliFAvvisatiGAmadoriS. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Eng J Med, 1990; 322: 1430–34.
37.
BrowmanGPBergsagelDSicheriD. Randomised trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada clinical trials group. J Clin Oncol, 1995; 13: 2354–60.
38.
SalmonSECrowleyJJGroganTMFinleyPPughRPBarlogieB. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol, 1994; 12: 2405–2414.
39.
WestinJRodjerSTuressonICortelezziAHjorthMZadorG. Interferon alfa-2b versus no maintenance therapy during plateau phase in multiple myeloma: a randomised study. Br J Haematol, 1995; 89: 561–68.
40.
PowlesRRajeNCunninghamD. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous marrow transplantation or peripheral stem cell rescue. Stem Cells, 1995; 13 (suppl 2): 114–117.
41.
WisloffFHjorthMKaasaSWestinJ. Effect of interferon on the healthrelated quality of life of multiple myeloma patients: results of a Nordic randomised trial comparing melphalan-prednisone to melphalan-prednisone + α-interferon. Br J Haematol, 1996; 94: 324–32.
42.
ShipmanCMRogersMJApperleyJFGrahamRRussellRCroucherPI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br J Haematol, 1997; 98: 665–672.
43.
BelchARBergsagelDEWilsonK. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol, 1991; 9: 1397–40.
44.
LahtinenRLaaksoMPalvaIVirkkunenPElomaaI. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet, 1992; 340: 1049–1052.
45.
McLoskeyEVMacLennanICMDraysonMChapmanCDunnJKanisJA. Effect of clodronate on morbidity and mortality in myelomatosis. Ann Oncol, 1996; 7 (suppl 5): Abstract 4120.
46.
BerensonJLichtensteinAPorterL. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med;, 1996; 334: 488–93.
47.
Medical Research Council's Working Party for Therapeutic Trials in Leukaemia. Report on the first myelomatosis trial. Part 1. Analysis of presenting features of prognostic importance. Br J Haematol1973; 24: 123–29.
48.
Medical Research Council's Working Party on Leukaemia in Adults. Prognostic features in the third MRC myelomatosis trial. Br J Cancer1980; 42: 831–40.
